首页> 外文期刊>Experimental and clinical transplantation >When Should We Consider the Diagnosis of Giant Cell Myocarditis? Revisiting 'Classic' Echocardiographic and Clinical Features of This Rare Pathology
【24h】

When Should We Consider the Diagnosis of Giant Cell Myocarditis? Revisiting 'Classic' Echocardiographic and Clinical Features of This Rare Pathology

机译:什么时候应该考虑诊断巨细胞心肌炎?回顾这种罕见病理的“经典”超声心动图和临床特征

获取原文
       

摘要

Objectives: Giant cell myocarditis is a rare and often fatal disorder. According to the American Heart Association, the American College of Cardiology Foundation, and the European Society of Cardiology scientific statements, an endomyocardial biopsy should be done to exclude giant cell myocarditis in unexplained new-onset heart failure of 2 weeks to 3 months duration associated with dilated left ventricle and new ventricular arrhythmias, or Mobitz type II second-degree, or third-degree atrioventricular heart block. Case Presentations: Two hundred thirty-five heart transplants were performed since May 1993 at the Institut universitaire de cardiologie et de pneumologie de Quebec, Canada. Giant cell myocarditis was found in the explanted hearts of 5 patients. The preoperative diagnosis of giant cell myocarditis was done by endomyocardial biopsy or at the installation of a left ventricular-assisted device. Patients had symptoms of progressive heart failure of subacute onset. Patients consulted at a mean 32 days after the onset of symptoms. Two patients neither had ventricular arrhythmia nor heart block. Two patients had ventricular arrhythmias and heart block; the other patient had symptomatic heart block. All patients had at least 2 echocardiographies. Two patients had an increase in left ventricular size, enough to reach the criteria of left ventricular dilatation according to the American Society of Echocardiography. During this time, left ventricular ejection fraction showed a rapid decline (mean 37% to 16%). Conclusions: Ventricular arrhythmia, heart block, and left ventricular dilatation initially can be absent in many patients having giant cell myocarditis with symptoms of progressive heart failure. Endo-myocardial biopsy should be quickly considered in patients with a rapid and dramatic decline of left ventricular ejection fraction, even in the absence of classic clinical and echocardiographic features of giant cell myocarditis to rapidly obtain the diagnosis of this rare but lethal disease.
机译:目的:巨细胞型心肌炎是一种罕见且通常致命的疾病。根据美国心脏协会,美国心脏病学会基金会和欧洲心脏病学会的科学声明,应进行心内膜活检,以排除原因不明的新发性心力衰竭的持续时间为2周至3个月的巨细胞心肌炎。左室扩张和新的室性心律失常,或Mobitz II型二度或三度房室心脏传导阻滞。病例报告:自1993年5月以来,在加拿大魁北克省心肺病研究所进行了235例心脏移植。在5例患者的离体心脏中发现了巨细胞心肌炎。巨大细胞心肌炎的术前诊断是通过心内膜活检或在左心室辅助装置处进行的。患者具有亚急性发作的进行性心力衰竭症状。患者在症状发作后平均32天进行咨询。两名患者既没有心律不齐,也没有心脏传导阻滞。 2例患者出现室性心律失常和心脏传导阻滞。另一位患者有症状性心脏传导阻滞。所有患者至少进行了2次超声心动图检查。根据美国超声心动图学会,两名患者的左心室增大,足以达到左心室扩张的标准。在此期间,左心室射血分数迅速下降(平均37%至16%)。结论:在许多具有进行性心力衰竭症状的巨细胞心肌炎患者中,最初可能没有心律失常,心脏传导阻滞和左心室扩张。对于左心室射血分数迅速且急剧下降的患者,应迅速考虑进行心内膜活检,即使在没有巨细胞心肌炎的典型临床和超声心动图特征的情况下,也可以迅速诊断出这种罕见但致命的疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号